India lifts export ban on COVID-19 drug Hydroxychloroquine: Trump’s “game changer”

India has lifted the export ban on Hydroxychloroquine. Manufacturers, except export-oriented units and those in special economic zones.  Would still have to supply 20% of their production to the domestic market, Minister Gowda said.

India has lifted the export ban on Hydroxychloroquine. It is the same anti-malarial drug that U.S. President Donald Trump claims as a potential “game changer”. In his nation’s fight against the COVID-19 pandemic.  Chemicals Minister said late on Wednesday. “Department of Pharmaceuticals has approved. The lifting of ban on Export of Hydroxychloroquine API. As well as formulations.” India’s minister for chemicals and fertilizers, Sadananda Gowda, said on Twitter.

Manufacturers, except export-oriented units and those in special economic zones.  Would still have to supply 20% of their production to the domestic market, Gowda said. India is a leading exporter of generic medicines across the world. However, it banned the export of the drug and its formulations in March. Since, the Novel Corona Virus outbreak disrupted supply chains. Moreover, India required it for its citizens to heal first.

Advertisement

USA Trade Deal For Hydroxychloroquine

But, India eased some of these restrictions in April. It shipped 50 million tablets of the drug to the United States of America. Also, Trump’s championing of hydroxychloroquine had initially raised expectations for the treatment. Although conflicting reports of its efficacy have added to confusion about the decades-old drug.

British scientists last week halted a major trial. Because, they found that the drug was “useless” at treating COVID-19 patients. A Lancet medical journal study that found hydroxychloroquine increased the risk of death in COVID-19 patients. It was withdrawn a week after it led to major trials being halted.

Meanwhile, the World Health Organization said it will resume the trial. The drug will be used against the Novel Corona Virus. After those running the study briefly stopped giving it to new patients over health concerns. Conclusively, India believes the now “useless” drug can help economically. Not only will it increase export revenue and build the medical industry. But also it will clear surplus of the drug.